Literature DB >> 30502907

Melatonin enhances responsiveness to Dichelobacter nodosus vaccine in sheep and increases peripheral blood CD4 T lymphocytes and IgG-expressing B lymphocytes.

Asunción Ramos1, María Prado Míguez2, Sara Morgado3, Beatriz Sanchez-Correa3, Juan J Gordillo3, Javier G Casado4, Raquel Tarazona5, Sergio Regodón1.   

Abstract

The immunomodulatory functions mediated by melatonin support its use as vaccine adjuvant. Previously, we have demonstrated that melatonin enhances antibody responses in sheep vaccinated against Dichelobacter nodosus. Here, we analyze the effect of melatonin on T and B lymphocyte subsets in peripheral blood of sheep vaccinated against D. nodosus. We also compare the use of melatonin in implants and in injections. Melatonin administration either as implants or by injection produced higher antibody titers against A1 and C serotypes compared to those animals that received only the vaccine. These results support the use of melatonin as an adjuvant in vaccination against D. nodosus. Firstly, melatonin induces higher antibody titer than the vaccine alone, secondly, melatonin increase IgG+ B lymphocytes and CD4+ T lymphocytes in vaccinated sheep. These results suggest that melatonin enhances T CD4 cell activation and subsequently secondary humoral immune responses. Further studies are required to determine the mechanism underlining the immunomodulatory role of melatonin in the context of vaccination.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B cells; Dichelobacter nodosus; Immunization; Melatonin; Sheep; T cells

Mesh:

Substances:

Year:  2018        PMID: 30502907     DOI: 10.1016/j.vetimm.2018.11.006

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

Review 1.  Psycho-Neuro-Endocrine-Immunology: A Role for Melatonin in This New Paradigm.

Authors:  Oscar K Bitzer-Quintero; Genaro G Ortiz; Socorro Jaramillo-Bueno; Elsy J Ramos-González; María G Márquez-Rosales; Daniela L C Delgado-Lara; Erandis D Torres-Sánchez; Aldo R Tejeda-Martínez; Javier Ramirez-Jirano
Journal:  Molecules       Date:  2022-07-30       Impact factor: 4.927

2.  Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines.

Authors:  Georges Maestroni
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-10       Impact factor: 4.147

Review 3.  Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality.

Authors:  Dun-Xian Tan; Russel J Reiter
Journal:  Life Sci       Date:  2022-01-30       Impact factor: 6.780

Review 4.  The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy.

Authors:  Eva Ramos; Francisco López-Muñoz; Emilio Gil-Martín; Javier Egea; Iris Álvarez-Merz; Sakshi Painuli; Prabhakar Semwal; Natália Martins; Jesús M Hernández-Guijo; Alejandro Romero
Journal:  Antioxidants (Basel)       Date:  2021-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.